Andrew H. Wei

Andrew H. Wei

Commercial Road
Melbourne, VIC 3004, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 269 publications

Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.

Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.

Journal: Leukemia & lymphoma

Published: July 26, 2026

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 13, 2026

Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a FLT3 N676K variant.

Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a FLT3 N676K variant.

Journal: Leukemia & lymphoma

Published: July 07, 2026

Neutropenia Duration During AZA-VEN Induction for AML Is Bimodal and Correlates With Infection Risk.

Neutropenia Duration During AZA-VEN Induction for AML Is Bimodal and Correlates With Infection Risk.

Journal: Blood advances

Published: May 05, 2026

MAP3K14 (NIK) synonymous variants drive altered splicing to activate NF-κB in mature B-cell malignancies.

MAP3K14 (NIK) synonymous variants drive altered splicing to activate NF-κB in mature B-cell malignancies.

Journal: Blood

Published: March 25, 2026

Timing of response in patients with relapsed/refractory FLT3 mut+ acute myeloid leukemia treated with gilteritinib.

Timing of response in patients with relapsed/refractory FLT3 mut+ acute myeloid leukemia treated with gilteritinib.

Journal: Blood neoplasia

Published: February 19, 2026

Adolescent ethanol exposure reprograms HMGB1 responsivity to adult ethanol challenge in males.

Adolescent ethanol exposure reprograms HMGB1 responsivity to adult ethanol challenge in males.

Journal: Physiology & behavior

Published: February 13, 2026

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

Journal: Blood

Published: February 04, 2026

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

Journal: Blood

Published: February 04, 2026

Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent IDH1 mutation.

Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent IDH1 mutation.

Journal: Blood neoplasia

Published: January 12, 2026

Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.

Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.

Journal: Leukemia & lymphoma

Published: December 18, 2025

Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?

Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Showing 1-12 of 269

Last Updated: 09/26/2026